<DOC>
	<DOCNO>NCT00000732</DOCNO>
	<brief_summary>To determine pharmacokinetics low dos zidovudine ( AZT ) ( , fast AZT reach blood , concentration AZT attain blood , long AZT remain blood ) change day-to-day patient . Also determine whether pharmacokinetics AZT change sulfamethoxazole/trimethoprim ( SMX/TMP ) give time whether pharmacokinetics SMX/TMP alter AZT therapy . AZT effective treating patient AIDS , SMX/TMP antibiotic combination useful prevent treat Pneumocystis carinii pneumonia ( PCP ) , important cause disease death patient AIDS . It important know drug interact patient addition second drug may change speed drug eliminate body , cause increase toxic effect decrease therapeutic effect .</brief_summary>
	<brief_title>Evaluation Interaction Between Low Dose Sulfamethoxazole-Trimethoprim Zidovudine</brief_title>
	<detailed_description>AZT effective treating patient AIDS , SMX/TMP antibiotic combination useful prevent treat Pneumocystis carinii pneumonia ( PCP ) , important cause disease death patient AIDS . It important know drug interact patient addition second drug may change speed drug eliminate body , cause increase toxic effect decrease therapeutic effect . Patients take AZT every 4 hour and/or SMX/TMP every 12 hour mouth 4 day outpatient come clinical research center 2 day study . On day 5 final dose medicine give orally ( SMX/TMP ) intravenous infusion ( AZT ) . Blood sample draw 10-20 time period 12 hour urine collect 36 hour . Concentrations drug blood urine sample determine . This sequence repeat twice , patient take AZT alone , SMX/TMP alone , combination AZT SMX/TMP period 3 week . Patients may include study asymptomatic , diagnosed ARC AIDS , PCP severe opportunistic infection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Prior Medication : Allowed : Zidovudine ( AZT ) patient AIDS . AIDS relate complex ( ARC ) . The presence one follow finding within 12 month prior entry absence concurrent illness condition HIV infection explain finding : Fever &gt; 38.5 C degree persist longer 3 week . Involuntary weight loss &gt; 15 lb . &gt; 10 percent baseline note 120day period prior evaluation . Diarrhea ( &gt; 2 liquid stool per day ) persisting longer 1 month . History clinical diagnosis oral candidiasis hairy leukoplakia . Patients AIDSdefining opportunistic infection tumor . Patients eligible AZT labeling . A positive HIV antibody test . Exceptions make patient previously positive HIV antibody test progressive disease patient virus isolation make . A life expectancy least 3 month . Patient stable Kaposi 's sarcoma , mild herpes infection , mild stable depression , asymptomatic mild cytomegalovirus EpsteinBarr virus infection , hepatitis B virus carrier state acceptable study . Exclusion Criteria Concurrent Medication : Excluded : Phenytoin . Prior Medication : Excluded within 30 day study entry : Other antiretroviral agent . Patient severe ongoing opportunistic infection include Pneumocystis carinii pneumonia ( PCP ) , cryptococcal toxoplasmosis meningoencephalitis , disseminate herpes simplex herpes zoster . Patient significant diarrhea entry ( &gt; 1 watery stool per day ) . Patient demonstrate prior sensitivity experience significant adverse effect prior therapy drug use study . Can abstain alcohol drug study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Sulfamethoxazole-Trimethoprim</keyword>
</DOC>